deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02644941

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)

Sponsor: CTI Clinical Trial and Consulting Services

Conditions End Stage Renal Disease Hemodialysis Renal Failure Vascular Access
Interventions Human Acellular Vessel (HAV) ePTFE graft
Updated 21 times since 2017 Last updated: Mar 28, 2025 Started: May 24, 2016 Primary completion: May 31, 2019 Completion: Sep 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates End Stage Renal Disease and Hemodialysis and is currently completed. CTI Clinical Trial and Consulting Services leads this study, which shows 21 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jan 2018 · 7 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Nov 2019 · 9 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jan 2022 · 9 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 16 earlier versions

  1. Nov 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  14. Jun 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CTI Clinical Trial and Consulting Services
  • California Institute for Regenerative Medicine (CIRM)
  • Humacyte, Inc.
Data source: Humacyte, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alsip, United States , Baltimore, United States , Birmingham, United Kingdom , Boston, United States , Dallas, United States , Durham, United States , Erlangen, Germany , Flint, United States , Frankfurt am Main, Germany , Fresno, United States and 27 more locations